Drug Profile
Research programme: anti-Mullerian inhibiting substance type II receptor humanised monoclonal antibodies - GamaMabs Pharma
Alternative Names: Anti-AMHRII humanised monoclonal antibody; Anti-MISRII humanised monoclonal antibody 12G4; GM103; hmAb 12G4; Humanised monoclonal antibody 12G4Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Institut de Recherche en Cancerologie de Montpellier
- Developer GamaMabs Pharma
- Class Monoclonal antibodies
- Mechanism of Action Anti-Mullerian hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in France (Parenteral)
- 21 Apr 2018 Pharmacodynamics data from preclinical studies in Ovarian cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
- 30 Sep 2013 Preclinical trials in Ovarian cancer in France (Parenteral)